These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20801000)

  • 1. Leishmaniasis vaccines: past, present and future.
    Modabber F
    Int J Antimicrob Agents; 2010 Nov; 36 Suppl 1():S58-61. PubMed ID: 20801000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines for leishmaniasis in the fore coming 25 years.
    Palatnik-de-Sousa CB
    Vaccine; 2008 Mar; 26(14):1709-24. PubMed ID: 18295939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis.
    Okwor I; Liu D; Uzonna J
    Vaccine; 2009 Apr; 27(19):2554-62. PubMed ID: 19428861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous leishmaniasis: progress towards a vaccine.
    Launois P; Tacchini-Cottier F; Kieny MP
    Expert Rev Vaccines; 2008 Oct; 7(8):1277-87. PubMed ID: 18844599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis.
    Noazin S; Khamesipour A; Moulton LH; Tanner M; Nasseri K; Modabber F; Sharifi I; Khalil EA; Bernal ID; Antunes CM; Smith PG
    Vaccine; 2009 Jul; 27(35):4747-53. PubMed ID: 19540273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends.
    Badiee A; Heravi Shargh V; Khamesipour A; Jaafari MR
    Vaccine; 2013 Jan; 31(5):735-49. PubMed ID: 23219436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying vaccine targets for anti-leishmanial vaccine development.
    Sundar S; Singh B
    Expert Rev Vaccines; 2014 Apr; 13(4):489-505. PubMed ID: 24606556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.
    Doroud D; Rafati S
    Expert Rev Vaccines; 2012 Jan; 11(1):69-86. PubMed ID: 22149710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
    Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress towards a Leishmania vaccine.
    Tabbara KS
    Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmaniasis vaccine candidates for development: a global overview.
    Khamesipour A; Rafati S; Davoudi N; Maboudi F; Modabber F
    Indian J Med Res; 2006 Mar; 123(3):423-38. PubMed ID: 16778321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
    Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
    Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.
    Palatnik-de-Sousa CB; Barbosa Ade F; Oliveira SM; Nico D; Bernardo RR; Santos WR; Rodrigues MM; Soares I; Borja-Cabrera GP
    Expert Rev Vaccines; 2008 Aug; 7(6):833-51. PubMed ID: 18665780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery systems for Leishmania vaccine development.
    Gholami E; Zahedifard F; Rafati S
    Expert Rev Vaccines; 2016 Jul; 15(7):879-95. PubMed ID: 26905526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-generation vaccines against leishmaniasis.
    Coler RN; Reed SG
    Trends Parasitol; 2005 May; 21(5):244-9. PubMed ID: 15837614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunology of Leishmania infection and the implications for vaccine development.
    Vanloubbeeck Y; Jones DE
    Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide Vaccines for Leishmaniasis.
    De Brito RCF; Cardoso JMO; Reis LES; Vieira JF; Mathias FAS; Roatt BM; Aguiar-Soares RDDO; Ruiz JC; Resende DM; Reis AB
    Front Immunol; 2018; 9():1043. PubMed ID: 29868006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically modified live attenuated parasites as vaccines for leishmaniasis.
    Selvapandiyan A; Duncan R; Debrabant A; Lee N; Sreenivas G; Salotra P; Nakhasi HL
    Indian J Med Res; 2006 Mar; 123(3):455-66. PubMed ID: 16778323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants.
    Poot J; Janssen LH; van Kasteren-Westerneng TJ; van der Heijden-Liefkens KH; Schijns VE; Heckeroth A
    Vaccine; 2009 Jul; 27(33):4439-46. PubMed ID: 19500553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.